For the endometrium, estradiol and tamoxifen induce proliferation, and consequently, tamoxifen treatment of breast cancer results in a 2-fold to 7-fold increased risk for endometrial cancer. Here, the role of activation of growth factor receptor signaling in mediating the e fects of estrogen and tamoxifen is determined. Microarray analysis of ECC-1 cells treated with estradiol or tamoxifen indicate that rapid responses to treatment (1 hour) are very distinct from long-term responses (>24 hours). Furthermore, estradiol and tamoxifen are observed to induce AKT activation. Comparing long-term estrogen- and tamoxifen-regulated genes with genes regulated by insulin-like growth factor 1 and amphiregulin reveals that the late e fects of estrogen and tamoxifen signaling may partly be mediated via activation of growth factor receptor signaling pathways. It is hypothesized that both early and late e fects of estrogen and tamoxifen signaling in the endometrium are partly mediated via the activation of growth factor receptor signaling, putatively at the level of AKT activation.

, , , , , ,
doi.org/10.1177/1933719107306872, hdl.handle.net/1765/37142
Reproductive Sciences
Erasmus MC: University Medical Center Rotterdam

Gielen, S.C.J.P, Santegoets, L.A.M, Kühne, L.C, van IJcken, W.F.J, Boers-Sijmons, B, Hanifi-Moghaddam, P, … Burger, C.W. (2007). Genomic and nongenomic effects of estrogen signaling in human endometrial cells: Involvement of the growth factor receptor signaling downstream AKT pathway. Reproductive Sciences, 14(7), 646–654. doi:10.1177/1933719107306872